203 related articles for article (PubMed ID: 31161692)
1. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen YD; Lock JP; Zhou W; Zhu F; Freeman MW
Diabetes Obes Metab; 2019 Oct; 21(10):2248-2256. PubMed ID: 31161692
[TBL] [Abstract][Full Text] [Related]
2. Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial.
Halvorsen YD; Conery AL; Lock JP; Zhou W; Freeman MW
Diabetes Obes Metab; 2023 Oct; 25(10):2954-2962. PubMed ID: 37409573
[TBL] [Abstract][Full Text] [Related]
3. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.
Halvorsen YC; Walford GA; Massaro J; Aftring RP; Freeman MW
Diabetes Obes Metab; 2019 Nov; 21(11):2496-2504. PubMed ID: 31297965
[TBL] [Abstract][Full Text] [Related]
4. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes.
Halvorsen YD; Walford G; Thurber T; Russell H; Massaro M; Freeman MW
Diabetes Obes Metab; 2020 Apr; 22(4):566-573. PubMed ID: 31749238
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
7. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
[TBL] [Abstract][Full Text] [Related]
8. A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen YD; Lock JP; Frias JP; Tinahones FJ; Dahl D; Conery AL; Freeman MW
Diabetes Obes Metab; 2023 Jan; 25(1):293-301. PubMed ID: 36178197
[TBL] [Abstract][Full Text] [Related]
9. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
[TBL] [Abstract][Full Text] [Related]
11. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
[TBL] [Abstract][Full Text] [Related]
13. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
Moses RG; Round E; Shentu Y; Golm GT; O'neill EA; Gantz I; Engel SS; Kaufman KD; Goldstein BJ
J Diabetes; 2016 Sep; 8(5):701-11. PubMed ID: 26625270
[TBL] [Abstract][Full Text] [Related]
15. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
[TBL] [Abstract][Full Text] [Related]
16. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Jabbour SA; Hardy E; Sugg J; Parikh S;
Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
Hartley P; Shentu Y; Betz-Schiff P; Golm GT; Sisk CM; Engel SS; Shankar RR
Drugs Aging; 2015 Jun; 32(6):469-76. PubMed ID: 26041585
[TBL] [Abstract][Full Text] [Related]
20. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
Allegretti AS; Zhang W; Zhou W; Thurber TK; Rigby SP; Bowman-Stroud C; Trescoli C; Serusclat P; Freeman MW; Halvorsen YC
Am J Kidney Dis; 2019 Sep; 74(3):328-337. PubMed ID: 31101403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
